Physician profile
Nancy Lau
NPI 1144208794
$5,258.72
in general payments reported to CMS, 2019-2025
24 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $380 · 2021: $1,093 · 2022: $1,013 · 2023: $675 · 2024: $960 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360 · Education: $19.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.88 |
| Education | $19.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,306.13 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $674.15 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $586.07 | 2021-2025 | |
| Abbvie INC. | $436.75 | 2021-2024 | |
| Redhill Biopharma INC. | $426.09 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Merck Sharp & Dohme LLC | $344.97 | 2022-2024 | Dificid |
| Braintree Laboratories, INC. | $271.78 | 2019-2024 | Sutab |
| Madrigal Pharmaceuticals | $164.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $151.39 | 2020-2024 | Linzess |
| Boston Scientific Corporation | $150.51 | 2019-2021 | |
| Janssen Biotech, INC. | $121.79 | 2021-2025 | Stelara, Tremfya |
| Intra-Sana Laboratories | $89.00 | 2022-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Phathom Pharmaceuticals, INC. | $87.24 | 2024 | Voquezna |
| Ardelyx, INC. | $82.17 | 2022-2025 | Ibsrela |
| Amgen INC. | $79.48 | 2025 | Uplizna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $71.19 | 2023-2024 | |
| Exact Sciences Corporation | $45.72 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $45.00 | 2024 | Entyvio |
| Vivus LLC | $24.77 | 2025 | Pancreaze |
| Daiichi Sankyo INC. | $24.45 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $22.52 | 2020 | |
| Allergan, INC. | $20.00 | 2019 | |
| Celltrion USA INC. | $19.17 | 2024 | Zymfentra |
| Intercept Pharmaceuticals, INC. | $13.74 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.